Nicole R. Hadas, VP General Counsel & Secretary at Akebia Therapeutics, Inc. (AKBA), sold 1,715 shares at $11.46 ($20K) on 2015-01-02, disclosed to the SEC on 2015-01-05.
Scheduled sale ($20k) by VP General Counsel & Secretary under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| AKBA | SELL | 2024-02-29 | $11K | — | Filing → |
| AKBA | SELL | 2023-05-25 | $154K | — | Filing → |
| AKBA | SELL | 2023-03-03 | $11K | — | Filing → |